Human Stem Cell Institute's RAS net income for 9 months of 2022 was ₽124.637 million, up 2.6 times from ₽47.707 million in the previous year. Revenue increased 18.2% to ₽59.931 million versus ₽50.682 million a year earlier.

HSCI is not planning to pay dividends this year and next year; it may consider the issue in 2024, the company's chairman, Artur Isaev, told Finam Online. "The dividend policy is simple - as long as we have expenses and investments our more than income, and it is profitable for us to invest, we will try to do so," he explained.

Developer of Russian coronavirus vaccine Betuvax company, part of HSCI, completed Phase I-II clinical trials, which confirmed the efficacy and safety of the drug. Vaccine was tested at three clinical centers in St. Petersburg and Perm with the participation of 116 volunteers who had not previously had covid and had not been vaccinated.

Human Stem Cell Institute's IFRS net income for 6 months of 2022 was ₽29.925 million, up 15.8% from ₽25.845 million in the previous year. Revenue decreased 6.6% to ₽519.89 million versus ₽556.75 million a year earlier.